March 3, 2023

CureLab Receives $3M from Prominent Biotech Investor Dr. John Ballantyne

Ballantyne is the co-founder and former chief scientific officer of Aldevron, a leading manufacturer of plasmids and other biologicals
November 5, 2022

Biotech Internship Opportunity! FDA/USDA liaison

CureLab Oncology and CureLab Veterinary are looking for interns to work with our FDA/USDA team on regulatory activities
September 10, 2022

ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival

While the disease has progressed in all patients receiving standard of care, it did not progress in 40% of the patients receiving standard chemotherapy together with the experimental drug, Elenagen — and for half of the patients in the group, Elenagen has increased the time to disease progression by more than 2.5 times
May 3, 2022

CureLab Oncology Secures Patent Protection for P62 Plasmid Therapeutic in South Korea

Patent registration in South Korea opens door to commercial agreements in an enormous market with high economic potential for CureLab
April 22, 2022

University of Camerino Signs Strategic Partnership with CureLab Veterinary to Revolutionize Cancer Treatment for Companion Animals

The university is also renewing its agreement with CureLab Oncology to support its phase II clinical trials
March 30, 2022

The Scientist: Russian Scientists Grapple with an Uncertain Future

As the terrible Ukraine-Russia situation evolves, what does this portend for scientists located in the region? Scientists from countries with differing political systems have long collaborated with colleagues located in politically distressed and war-torn regions. Despite the associated challenges, these collaborations have combined their respective strengths and even leveraged the unique characteristics of their regional differences.
January 31, 2022

CureLab Oncology and the American Eurasian Cancer Alliance Partner to Fight Ovarian Cancer

Partnership aims to accelerate CureLab’s clinical studies by providing access to intellectual and scientific resources that can advance research and discovery in ovarian cancer prevention and treatment strategies
November 23, 2021

CureLab Oncology Secures Patent Protection in India

Patent registration in India opens door to commercial agreements in an enormous market with rising incidence of cancer
November 11, 2021

OncologyTube interviews Dr. Alex Shneider of CureLab Oncology and Prof. Sergei Krasny

Along with the OncologyTube host Stephanie Comello, Dr. Alex Shneider and Prof. Sergei Krasny discuss results from our clinical studies underway in Belarus. If you have 30 minutes, we invite you to watch the video. We’ve condensed the highlights below.
September 16, 2021

CureLab Oncology Presents at 2021 ESMO Congress

The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy
April 29, 2020

CureLab Oncology’s Dr. Alex Shneider Publishes Paper: Can Melatonin Reduce the Severity of COVID-19?

Melatonin may prevent the development of severe disease symptoms in coronavirus patients, reduce the severity of their symptoms, and/or reduce the immuno-pathology of coronavirus infection on patients’ health after the active phase of the infection is over
October 5, 2020

CureLab Oncology Receives Pre-IND Response from FDA Regarding Planned Trial for Triple Negative Breast Cancer

Feedback from FDA was constructive and includes recommendations to test cumulative toxicity and clinical benefits progression; this has led the company to consider a shorter trial design for Phase II.
October 14, 2020

CureLab Oncology Appoints The Honorable David J. Shulkin, M.D. to its Scientific Advisory Board

Former US Secretary of Veterans Affairs and internationally known healthcare industry leader to advise on partnerships for upcoming clinical trials and market entry strategy for CureLab’s Elenagen cancer therapy
October 21, 2020

CureLab Oncology Establishes Operations in the Gulf Region

CureLab is expanding its global presence with a new office in the Gulf Cooperation Council (GCC) region; CureLab's partners in the region will test the efficacy of the company's DNA-based products against cancers and non-cancerous diseases of chronic inflammation